ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia
Phase 3
Completed
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: FK199BDrug: Zolpidem
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 55
- Registration Number
- NCT00999219
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1215
- Registration Number
- NCT00985387
Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ASP1517Drug: Placebo
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00978198
A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers
Phase 1
Completed
- Conditions
- Healthy VolunteerPharmacokinetics of YM178
- Interventions
- Drug: YM178
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2013-07-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00965926
A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation
Phase 1
Completed
- Conditions
- OsteoporosisOsteoporosis, PostmenopausalBone Diseases
- Interventions
- Drug: ONO-5920 / YM529
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2009-10-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00965978
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1139
- Registration Number
- NCT00966004
A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients
Phase 4
Completed
- Conditions
- Sleep Initiation and Maintenance DisordersPrimary Insomnia
- Interventions
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 42
- Registration Number
- NCT00956319
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
Phase 3
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: YM150Procedure: mechanical prophylaxis
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 156
- Registration Number
- NCT00942435
Study of the Effect of Food on the Pharmacokinetics of Mirabegron
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 76
- Registration Number
- NCT00939757
Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 91
- Registration Number
- NCT00940121
© Copyright 2025. All Rights Reserved by MedPath